<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03041155</url>
  </required_header>
  <id_info>
    <org_study_id>43697715.0.0000.5054</org_study_id>
    <nct_id>NCT03041155</nct_id>
    <nct_alias>NCT03075982</nct_alias>
  </id_info>
  <brief_title>Respiratory Muscle Training in Hemodialysis Patients</brief_title>
  <official_title>Respiratory Muscle Training in Hemodialysis Patients: Effects on Physiologic Parameters and Endothelium-related Biomarkers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Universidade Federal do Ceara</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Universidade Federal do Ceara</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The research protocol is a Randomized Clinical Trial that has the effectiveness of a given
      respiratory muscle training protocol over the indicative variables: Pulmonary function;
      Markers of oxidative stress and inflammation, endothelial markers and Quality of life in
      patients with chronic kidney disease undergoing hemodialysis. According to the Investigators,
      this topic was proposed since it is known that several pulmonary complications occur as a
      consequence of chronic kidney disease due to uremic myopathy. Therefore, the hypothesis is
      that the application of a respiratory muscle training protocol will contribute positively
      pulmonary functionality and a decrease in oxidative stress and inflammation in chronic kidney
      patients, consequently, will bring improvement in the quality of life for these patients. The
      Patients will be divided into two groups: control group - No intervention of the Muscular
      Training (CG) And Intervention Group (GI). The intervention protocol will be composed of
      respiratory muscle training And lasts for two (2) months, with three (3) visits per week. It
      will be carried out through Threshold PeP appliance. The twelve (12) first training sessions
      will have a total duration of 30 minutes 15 minutes with inspiratory load of 20 cmH2O and 15
      minutes with expiratory load of 20 CmH 2 O; and the others (12) twelve sessions will last 40
      minutes each, with 20 minutes with an inspiratory load of 20 CmH2O and 20 minutes with
      expiratory load of 20 cmH2O. The variables evaluated will be: muscular strength Respiratory
      (maximum inspiratory pressure and maximum expiratory pressure - Pimáx and Pemáx); Lung
      function (Slow Vital Capacity - CVL, forced expiratory volume in the first minute - VEF1,
      Vital Capacity Forced - CVF and Maximum Voluntary Ventilation - VVM); Serum levels of
      oxidative stress markers, endothelial markers and endothelin.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 1, 2017</start_date>
  <completion_date type="Actual">April 20, 2017</completion_date>
  <primary_completion_date type="Actual">April 20, 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>endothelium glycocalyx biomarkers</measure>
    <time_frame>8 weeks</time_frame>
    <description>plasma syndecan-1 (ng/mL)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Endothelium biomarker</measure>
    <time_frame>8 weeks</time_frame>
    <description>ICAM (ng/mL)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Endotehlium Biomarker</measure>
    <time_frame>8 weeks</time_frame>
    <description>VCAM(ng/mL)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Aberrant angiogenesis</measure>
    <time_frame>8 weeks</time_frame>
    <description>Angiopoietin-2 (ng/mL)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Oxidative stress</measure>
    <time_frame>8 weeks</time_frame>
    <description>Plasma Malondialdehyde (mmol/L)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean blood pressure</measure>
    <time_frame>8 weeks</time_frame>
    <description>Blood pressure (mmHg)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">48</enrollment>
  <condition>Renal Failure</condition>
  <arm_group>
    <arm_group_label>treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Muscle respiratory training</description>
  </arm_group>
  <arm_group>
    <arm_group_label>control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>No intervention</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Muscle respiratory training</intervention_name>
    <description>Muscle respiratory training during hemodialysis sessions</description>
    <arm_group_label>treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Maintenance hemodialysis for more than 3 months

          -  No COPD diagnosis

        Exclusion Criteria:

          -  Decompensated Heart failure

          -  Acute coronary disease in the last 3 months

          -  Active infection
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alexandre Liborio, PHD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Universidade Federal do Ceara</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Pronefron</name>
      <address>
        <city>Fortaleza</city>
        <state>Ceara</state>
        <zip>60165082</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <verification_date>July 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 30, 2017</study_first_submitted>
  <study_first_submitted_qc>January 31, 2017</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 2, 2017</study_first_posted>
  <last_update_submitted>July 15, 2017</last_update_submitted>
  <last_update_submitted_qc>July 15, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 19, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Universidade Federal do Ceara</investigator_affiliation>
    <investigator_full_name>Alexandre Braga Liborio</investigator_full_name>
    <investigator_title>Visitant Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Renal Insufficiency</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

